ClinicalTrials.gg
CompletedNCT04945226Updated Mar 4, 2022

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001

A Phase 1/2 interventional study of Finasteride 1mg Tablet and IVL3001 in Androgenetic Alopecia, sponsored by Inventage Lab., Inc.. Completed at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-04.

Sponsored by Inventage Lab., Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Alopecia with a site in Australia — 3 open to participants now, 4 under way, 1 of them phase 3. Alopecia · Australia.

Enrollment
11th of 14
40 · median 131
Started
2021
the only one that year
Phase 1/2
4 of 16
2 open now
Registered
8th of 16
by date
Lead sponsor
1 of 16
Inventage Lab., Inc.

Among the 16 studies in Alopecia with a site in Australia, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 1/2, and was the 8th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

3 of the 16 studies in Alopecia with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alopecia with a site in Australia, or all of them as a file.
02

Study summary

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001

Read the detailed description

A Randomized, Open-Label, Exploratory, Pharmacokinetic, Sequential Single Ascending dose Study of IVL3001 Versus Propecia (Finasteride) Tablets in Healthy Adult Participants

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male, non-smoker or, if a moderate or occasional smoker (\< 10 cigarettes per day or nicotine equivalent) must agree to abstain from smoking from 48 h before first IP administration through to completion of the final EOS/ET visit, aged ≥ 18 to 55 years (inclusive at the time of )
  • In good general health, in the opinion of the Investigator, with no significant medical history, and have no abnormalities on complete physical examination, 12-lead , heart rate, and BP, both at Screening and before administration of the initial dose of IP
  • (BMI) between ≥ 18 kg/m2 and ≤ 32 kg/m2 and a minimum weight ≥ 50 kg and ≤ 100 kg at Screening
  • Clinical laboratory values within normal limits, with normal range as specified by the testing laboratory, unless deemed not clinically significant by the Investigator or delegate
  • Ability and willingness to attend the necessary visits to the CRU and be domiciled overnight
  • Willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any protocol-specific study procedures

Exclusion criteria

Exclusion Criteria:

  • Prior or ongoing medical conditions, medical history, physical examination findings, or laboratory abnormalities that, in the Investigator's (or delegate's) opinion, could adversely affect the safety of the participant
  • Presence or history of any blood, kidney, endocrine, lung, gastrointestinal tract, cardiovascular, liver, or neurological condition
  • Presence of any underlying physical or psychological (eg, depression) medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per protocol. Mild depression and anxiety that has been resolved at least 6-12 months ago is accepted.
  • Presence of any medical condition that may affect oral drug absorption (eg, gastrectomy, gall bladder removal, bariatric surgery, gastric bypass and sleeve, bowel resection)
  • to finasteride or to any of the IPs
  • Age adjusted PSA between 0 2.5 ng/mL for subjects ≤ 50 years of age and between 0-4 ng/mL for subjects > 50 years of age at Screening, unless deemed not clinically significant by the Investigator or delegate
  • History or known presence of any prostatic problem (infection, prostate cancer, stricture disease, hypotonic bladder or other neurogenic disorder that might mimic BPH)
  • Positive test for antibody (HCV), surface antigen (HBsAg), antigen or antibody at Screening
  • Positive toxicology screening panel (urine test including qualitative identification of barbiturates, tetrahydrocannabinol [THC], amphetamines, benzodiazepines, opiates and cocaine), or a positive alcohol breath (or urine), or cotinine test
  • History of alcohol or substance abuse or dependency, or history of recreational intravenous (IV) drug use over the last 1 year (by self-declaration)
  • Regular alcohol consumption defined as > 21 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit, or a 125 mL glass of wine) within 6 months of Screening.
  • Use of any IP or medical device within 3 months prior to Screening, or five half-lives of the product (whichever is the longest), or participation in more than 4 investigational drug studies within 1 year prior to Screening
  • Use of any drug known to significantly induce or inhibit drug absorption or metabolism within 30 days prior to dosing
  • An employee, or relative of an employee, directly involved in the conduct of the study
  • Unwilling to refrain from strenuous exercise from 48 hours prior to admission to the CRU at Day -1 and 48 hours prior to each follow-up
  • Presence of sexual dysfunction such as decreased libido, erectile dysfunction, or ejaculation disorder
  • Estimated (eGFR) \< 90 mL/min/1.73m2 at Screening
  • Any reason which, in the opinion of the PI, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Propecia

    Propecia Tablet, QD, PO

    Drug: Finasteride 1mg Tablet

  • Experimental
    IVL3001 (A mg)

    S.C, Single Dose.

    Drug: IVL3001

  • Experimental
    IVL3001 (B mg)

    S.C, Single Dose.

    Drug: IVL3001

  • Experimental
    IVL3001 (C mg)

    S.C, Single Dose.

    Drug: IVL3001

Interventions

06

What researchers measure

Primary outcomes

  1. AUClast of IVL3001

    Area under the concentration-time curve from time zero to last

    Time frame: Pre-dose, 1008 hours

  2. AUCinf of IVL3001

    Area under the concentration-time curve from time zero to infinity

    Time frame: Pre-dose, 1008 hours

  3. AUC0-1008h of IVL3001

    Area under the concentration-time curve from time zero to 1008 hours

    Time frame: Pre-dose, 1008 hours

  4. AUClast of Propecia

    Area under the concentration-time curve from time zero to last

    Time frame: Pre-dose, 816 hours

  5. AUCinf of Propecia

    Area under the concentration-time curve from time zero to infinity

    Time frame: Pre-dose, 816 hours

  6. AUC0-672h of Propecia

    Area under the concentration-time curve from time zero to 672hours

    Time frame: Pre-dose, 672 hours

07

Study locations

1 site
  • Nucleus Network
    Brisbane, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Feb 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2021
First posted
Jun 30, 2021
StartActual
Sep 21, 2021
Primary completionActual
Feb 8, 2022
CompletionActual
Feb 8, 2022
Last update
Mar 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04945226
Lead sponsor
Inventage Lab., Inc.
Responsible party
Sponsor
First posted
Jun 30, 2021
Start date
Sep 21, 2021
Primary completion
Feb 8, 2022
Completion
Feb 8, 2022
Last update
Mar 4, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion